3rd Quarter - Report

AKIN GUMP STRAUSS HAUER & FELD for KYVERNA THERAPEUTICS, INC.

Firm
Client
Income
$60,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to developing cell and gene therapies for patients, including Stiff Person Syndrome, rare disease, and multiple sclerosis; related FY27 appropriations report language, including Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027 (H.R. 8646).

LobbyistCovered position, as disclosed
ANNA ABRAM —
KANDIS MCCLURE —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 8646 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.